Episode 46: ESMO 2026 Commentary: Kidney Cancer
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
-
Letto da:
-
Di:
Continuing their coverage from ESMO 2026 in Madrid, Dr. Aly-Khan Lalani and Dr. Christopher Wallis turn their attention to kidney cancer, highlighting the latest research and emerging approaches to the treatment of renal cell carcinoma (RCC).
The discussion begins with long-term follow-up data from KEYNOTE-564, examining the sustained benefits of adjuvant pembrolizumab and the importance of balancing treatment outcomes with patient experience. They also explore findings from the PE-PE trial, considering the potential role of immunotherapy alongside metastasis-directed treatment in oligometastatic RCC.
Turning to advanced disease, Dr. Lalani and Dr. Wallis review the LITESPARK-012 and LITESPARK-011 trials, discussing treatment combinations, progression-free and overall survival outcomes, and the challenges of balancing efficacy with toxicity. The conversation also highlights emerging research onbispecific T-cell engagers, including early findings from the XmAb819 trial, offering a glimpse into the future of kidney cancer treatment.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.